Short-term use of CGM in youth onset type 2 diabetes is associated with behavioral modifications

Front Endocrinol (Lausanne). 2023 May 29:14:1182260. doi: 10.3389/fendo.2023.1182260. eCollection 2023.

Abstract

Background: Continuous glucose monitoring (CGM) is beneficial to glycemic control in youth with type 1 diabetes (T1D) and adults with type 2 diabetes (T2D); however, studies in youth with T2D are limited.

Objective: Determine if 10-day trial CGM use in youth with T2D improves glycemic control and behavioral modifications.

Methods: Youth with T2D > 3 months, on insulin, with no prior CGM use were enrolled. Staff placed CGM and provided education. Participants received 5-day and 10-day follow-up phone calls to review CGM data, behavioral modifications, and adjust insulin doses as needed. We compared 5-day to 10-day TIR, and baseline to 3-6 month HbA1c via paired t-test.

Results: Participants (n=41) had median age of 16.2 y, were 61% female, 81% NH Black, median diabetes duration of 0.8 y, and baseline HbA1c of 10.3%. A majority had household income<$50,000 (81%) and parental education level of HS or less (73%). Average 5-day TIR 49% was similar to 10-day TIR 51% (p=0.62). There was no change in HbA1c after 3-6 months (10.2% v 10.3%, p=0.89). Nineteen participants completed full 10-day CGM use; of those, 84% wanted a CGM long-term. Adolescents reported behavioral changes including increased blood sugar checks, increased insulin administration and overall improved diabetes management.

Conclusion: Although 10-day CGM use did not impact short-term or long-term glycemic control in youth with T2D, most participants reported behavioral changes and wanted to continue using CGM. Future studies with longer use of CGM may clarify the potential impact of CGM in youth with T2D.

Keywords: adolescents; barriers; continuous glucose monitors; glycemic control; type 2 diabetes; youth.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Blood Glucose
  • Blood Glucose Self-Monitoring
  • Diabetes Mellitus, Type 2* / drug therapy
  • Female
  • Glycated Hemoglobin
  • Humans
  • Insulin / therapeutic use
  • Male

Substances

  • Glycated Hemoglobin
  • Blood Glucose
  • Insulin

Grants and funding

This work was supported by a Johns Hopkins Children’s Center Innovation Award to RMW, and an investigator-initiated research grant from Dexcom, Inc to RMW. The funder was not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication.